東富龍(300171.SZ):上半年在海外地區實現營收5.81億元,營收佔比達19.60%
格隆匯9月7日丨東富龍(300171.SZ)於2023年9月7日召開業績説明會,就“公司海外收入為何下滑?海外客户訂單增長與拓展情況如何?”,公司回覆稱,近年來,隨着國際市場競爭日趨激烈,貿易摩擦日益增多。面對複雜嚴峻的內外部環境,公司積極加強國內外市場推廣和營銷力度,積極參與行業內有影響力的專業展會及技術論壇,穩定和擴大市場佔有率、海外客户數量和覆蓋地區,在國際舞台上展現中國製藥裝備的卓越品質。2023年上半年,在海外地區實現營業收入5.81億元,營收佔比達19.60%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.